Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 22, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

June 30, 2028

Conditions
IDH1-mutant GliomaIDH2-mutant Glioma
Interventions
DRUG

Vorasidenib

To be taken by mouth once daily in 28-day cycles with no break between cycles

DRUG

Temozolomide (TMZ)

To be taken by mouth once daily for the first 5 days of each 28-day cycle, for a maximum of 12 cycles

Trial Locations (32)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10126

RECRUITING

Ospedale Molinette - Centro Oncologico Ematologico, Turin

20089

RECRUITING

Instituto Clinico Humanitas IRCCS, Rozzano

27710

RECRUITING

Duke University Medical Center, Durham

28041

RECRUITING

Hospital 12 de Octubre, Madrid

31059

RECRUITING

IUCT-Oncopole Institut Universitaire du Cancer, Toulouse

33136

RECRUITING

University of Miami, Miami

35128

RECRUITING

IOV - Ospedale Busonera, Padua

64239

NOT_YET_RECRUITING

The Tel Aviv Sourasky Medical Center (TASMC) (Ichilov Hospital), Tel Aviv

68167

RECRUITING

Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim

69003

RECRUITING

Hôpital Pierre Wertheimer, Lyon

69120

RECRUITING

Universitätsklinikum Heidelberg, Heidelberg

75013

RECRUITING

Hôpital Pitié-Salpêtrière, Paris

77030

RECRUITING

MD Anderson Cancer Center, Houston

90095

RECRUITING

University of California Los Angeles, Los Angeles

93053

RECRUITING

Universitätsklinikum Regensburg, Regensburg

94143

WITHDRAWN

University of California, San Francisco (UCSF) School of Medicine, San Francisco

100050

RECRUITING

Beijing Tiantan Hospital, Capital Medical University, Beijing

200040

RECRUITING

Huashan Hospital, Fudan University, Shanghai

503015

RECRUITING

Erasmus MC, Rotterdam

610041

WITHDRAWN

West China Hospital of Sichuan University, Chengdu

4941492

NOT_YET_RECRUITING

Rabin Medical Center - Davidoff Cancer Center, Petah Tikva

02114

WITHDRAWN

Massachusetts General Hospital, Boston

02215

RECRUITING

Dana Farber Cancer Institute, Boston

01090

RECRUITING

Medical University of Vienna - AKH, Vienna

860-8556

RECRUITING

Kumamoto University Hospital, Kumamoto

606-8507

RECRUITING

Kyoto University Hospital, Kyoto

466-8550

RECRUITING

Nagoya University Hospital, Nagoya

104-0045

RECRUITING

National Cancer Center Hospital, Tokyo

08035

RECRUITING

H. Valle de Hebron, Barcelona

M20 4BX

RECRUITING

Christie Hospital, Manchester

SM2 5PT

RECRUITING

The Royal Marsden in Sutton, Sutton

All Listed Sponsors
lead

Institut de Recherches Internationales Servier

OTHER